Facebook From Oral to Intravenous: How Fosaprepitant Dimeglumine Is Expanding Access to NK-1 Antagonist Therapy for Chemotherapy-Induced Nausea and Vomiting
Logo

From Oral to Intravenous: How Fosaprepitant Dimeglumine Is Expanding Access to NK-1 Antagonist Therapy for Chemotherapy-Induced Nausea and Vomiting

クレジット
Avatar
インタビューワー
From Oral to Intravenous: How Fosaprepitant Dimeglumine Is Expanding Access to NK-1 Antagonist Therapy for Chemotherapy-Induced Nausea and Vomiting-1
シェア
金金の他の作品